Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
PEACE6-Vulnerable trial: what clinicians have said so far
ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability (PEACE6-Vulnerable)
- NCT04916613 ↗
- Recruiting
- UNICANCER
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on PEACE6-Vulnerable (darolutamide in de novo metastatic prostate cancer, vulnerable functional ability) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PEACE6-Vulnerable so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Double-blind Randomised Phase III Trial Evaluating the Efficacy of ADT +/- Darolutamide in de Novo Metastatic Prostate Cancer Patients With Vulnerable Functional Ability and Not Elected for Docetaxel or Androgen Receptor Targeted Agents
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Darolutamide 300 mg; Placebo; Androgen deprivation therapy
- Arms
- ADT + darolutamide · Experimental
- ADT + placebo · Placebo comparator
- Enrollment
- 300 (estimated)
- Primary outcomes
- Radiographic progression-free survival
- Sponsor
- UNICANCER with Bayer
- Start
- Apr 19, 2022
- Primary completion
- Mar 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04916613 · updated Apr 28, 2026